# Otonomy

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/otonomy

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.otonomy.com
- Total disclosed funding: $108M
- Latest round: Series D (Apr 30, 2014)
- Investors on record: 13

## About

Otonomy Inc. specializes in developing innovative therapies for ear diseases, focusing on conditions such as hearing loss and tinnitus through advanced drug delivery technologies.Founded in 2008, Otonomy Inc. is based in San Diego, US, and operates in the field of otology, providing groundbreaking treatments for ear-related conditions. The company was founded by Allen Ryan, who has a history of involvement in the biotechnology sector. Otonomy has raised a total of USD 30.10 mn through multiple funding rounds, with its most recent deal being a Private Placement in April 2021. The company has engaged in nine deals, with the latest funding round aimed at supporting its innovative treatment solutions.Otonomy Inc. offers a range of therapies aimed at treating ear diseases, particularly focusing on drug delivery systems for conditions like hearing loss and tinnitus. Their flagship products include a sustained-release formulation designed to improve patient outcomes in managing chronic ear conditions, targeting healthcare providers and patients looking for effective solutions in the otology space.In the most recent fiscal year ending 2021, Otonomy reported a revenue of USD 125,000, alongside an EBITDA of USD -48,512,000. The company generates revenue primarily through its innovative therapies and partnerships with healthcare providers, aiming to increase access to its groundbreaking treatments.Otonomy Inc. is strategically planning to expand its product offerings with new therapies set to launch in the upcoming years, targeting global markets with significant unmet medical needs. The company has identified Europe and Asia as key regions for expansion by 2023. Recent funding raised in April 2021 will be utilized to accelerate clinical development and broaden market access for its innovative products, building on the success of previous offerings.

## Funding rounds

- Series D, Apr 30, 2014, $49M — Domain Associates, OrbiMed Advisors, Avalon Ventures, RiverVest Ventures Partners, Aperture Venture Partners, Novo Holdings, OUP (Osage University Partners), TPG Biotech, Jennison Associates, Federated Hermes, Ally Bridge Group, Clough Capital Partners, Perceptive Advisors
- Series C, Sep 4, 2013, $39M — Domain Associates, OrbiMed Advisors, Avalon Ventures, RiverVest Ventures Partners, Aperture Venture Partners, Novo Holdings, OUP (Osage University Partners), TPG Biotech
- Series B, Aug 30, 2010, $10M — Domain Associates, Avalon Ventures, RiverVest Ventures Partners, Novo Holdings, TPG Biotech
- Series A, Jun 11, 2010, $11M — Avalon Ventures

## Investors

- Avalon Ventures (https://capitalatlas.ai/funds/avalon-ventures) — Series A, Series B, Series C, Series D
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series B, Series C, Series D
- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series B, Series C, Series D
- Novo Holdings — Series B, Series C, Series D
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series B, Series C, Series D
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C, Series D
- Aperture Venture Partners (https://capitalatlas.ai/funds/aperture-venture-partners) — Series C, Series D
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series C, Series D
- Jennison Associates — Series D
- Federated Hermes (https://capitalatlas.ai/funds/federated-hermes) — Series D
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series D
- Clough Capital Partners — Series D
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series D